M G Peters
Affiliation: University of California
- Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulinM G Peters
University of California at San Francisco, 94143, USA
Transplantation 68:1912-4. 1999..Mutations in the hepatitis B virus (HBV) genome may occur during therapy...
- Animal models of autoimmune liver diseaseMarion G Peters
Division of Gastroenterology, University of California, San Francisco, California 94143 0538, USA
Immunol Cell Biol 80:113-6. 2002..The plethora of antigens implicated in autoimmune hepatitis in humans predicts that multiple mechanisms may play a role in precipitating disease in the susceptible individual...
- Alcohol use and hepatitis CMarion G Peters
Department of Gastroenterology, University of California, San Francisco, CA 94143, USA
Hepatology 36:S220-5. 2002..The literature is inadequate to provide definitive recommendations regarding the effect of light to moderate alcohol use in patients with hepatitis C...
- Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis BMarion G Peters
Division of Gastroenterology, University of California, San Francisco, CA 94143, USA
Gastroenterology 126:91-101. 2004....
- Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysisDebika Bhattacharya
University of California, Los Angeles, CA, USA
J Acquir Immune Defic Syndr 55:170-5. 2010..In HIV/ hepatitis C virus (HCV) coinfection, adverse events (AEs) during HCV therapy account for 12%-39% of treatment discontinuations. It is unknown whether sex influences complications...
- Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United StatesMarion G Peters
University of California at San Francisco, San Francisco, CA 94143 0538, USA
Hepatology 46:769-75. 2007..Possible mechanisms underlying this health discrepancy are not clear, but increased awareness of PBC as a cause of chronic cholestatic liver disease is critical in evaluating non-Caucasian patients in the United States...
- Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjectsCaroline M Behler
Department of Hematology and Oncology, University of California San Francisco, San Francisco, CA 94143 1270, USA
Clin Infect Dis 44:1375-83. 2007....
- Viral hepatitis in HIV infectionMargaret James Koziel
Division of Infectious Disease, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
N Engl J Med 356:1445-54. 2007
- Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Marion G Peters
University of California, San Francisco, San Francisco, CA, USA
Hepatology 44:1110-6. 2006..In conclusion, over 48 weeks, treatment with either ADV or TDF resulted in clinically important suppression of serum HBV DNA. Both drugs are safe and efficacious for patients coinfected with HBV and HIV...
- Influence of cannabis use on severity of hepatitis C diseaseJulie H Ishida
Department of Medicine, University of California at San Francisco, San Francisco, California, USA
Clin Gastroenterol Hepatol 6:69-75. 2008..Complications of HCV infection are primarily related to the development of advanced fibrosis and whether cannabis use is a risk factor for more severe fibrosis is controversial...
- Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosisBurton Combes
The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9151, USA
Hepatology 42:1184-93. 2005..In conclusion, methotrexate when added to UDCA for a median period of 7.6 years had no effect on the course of PBC treated with UDCA alone...
- Managing hepatitis B coinfection in HIV-infected patientsMarion G Peters
Division of Gastroenterology, Box 0538, University of California, 513 Parnassus Ave, Room S 357, San Francisco, CA 94143 0538, USA
Curr HIV/AIDS Rep 2:122-6. 2005..Long-term management of hepatitis B includes monitoring for hepatocellular carcinoma. Two recent consensus conferences have provided excellent reviews of management of coinfection ...
- Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patientsKenneth E Sherman
Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
Gastroenterology 128:313-27. 2005..HCV-monoinfected patients. Reasons for this remain unclear. This study evaluated kinetic parameters and treatment responses in co-infected vs monoinfected patients...
- Antiviral therapy: nucleotide and nucleoside analogsDavid J Quan
Department of Clinical Pharmacy, University of California, San Francisco, 521 Parnassus Avenue, Room C-152, Box 0622, San Francisco, CA 94143-0622, USA
Clin Liver Dis 8:371-85. 2004..Other nucleoside analogs are in various stages of development, including MCC-478 and DAPD. In the future, clinicians will have a plethora of reagents to chose from, and combination therapies may be invoked...
- Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected personsRaymond T Chung
Massachusetts General Hospital, Boston, MA 02114, USA
N Engl J Med 351:451-9. 2004..We conducted a multicenter, randomized trial comparing peginterferon plus ribavirin with interferon plus ribavirin for the treatment of chronic hepatitis C in persons coinfected with HIV...
- The challenge of diagnosing autoimmune hepatitis: less is moreGina Choi
Hepatology 48:10-2. 2008
- Diagnosis and management of hepatitis B virus and HIV coinfectionMarion G Peters
Hepatology Research, University of California San Francisco, San Francisco, CA, USA
Top HIV Med 15:163-6. 2007..This article summarizes a presentation on HIV and HBV coinfection made by Marion G. Peters, MD, at an International AIDS Society-USA Continuing Medical Education course in San Francisco in May 2007...
- Role of alphavbeta6 integrin in acute biliary fibrosisBruce Wang
Liver Center, Department of Medicine, University of California, San Francisco, USA
Hepatology 46:1404-12. 2007..The findings provide a rationale for the use of inhibitors of alphavbeta6 integrin or TGFbeta for down-regulating fibrosis in the setting of acute or ongoing biliary injury...
- Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosisBurton Combes
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9151, USA
Am J Gastroenterol 99:264-8. 2004....
- Viral factors associated with cytokine expression during HCV/HIV co-infectionJason T Blackard
Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
J Interferon Cytokine Res 27:263-9. 2007..Further studies are warranted to identify noninvasive markers of liver disease for the clinical management of HCV disease, particularly when liver biopsies have not been performed or are contraindicated...
- Effects of HCV treatment on cytokine expression during HCV/HIV coinfectionJason T Blackard
Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
J Interferon Cytokine Res 26:834-8. 2006....
- Novel model of antigen-specific induction of bile duct injuryJames Buxbaum
Department of Medicine, University of California, San Francisco, California 94143-0538, USA
Gastroenterology 131:1899-906. 2006..Thus, OVA BIL represents an antigen-specific animal model of inflammatory bile duct injury...
- Hepatitis C and alcohol: fundamental and translational research directionsTimothy R Morgan
Department of Medicine, Veterans Adminstration Medical Center, Long Beach, California, USA
Alcohol Clin Exp Res 27:726-31. 2003..This article summarizes the panel's deliberations and their recommendations for future research on alcohol and hepatitis C...
- Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplantJennifer E Guy
Department of Medicine, University of California San Francisco, CA 94143-0538, USA
Liver Transpl 11:1252-7. 2005..In conclusion, recurrent PBC is not infrequent post-OLT, and ursodeoxycholic acid can be used with some benefit post-OLT. Treatment effects on long-term survival are not known...
- De novo malignancies following liver transplantation: a case-control study with long-term follow-upFrancis Y Yao
Department of Medicine, University of California San Francisco, San Francisco, CA 94143-0538, USA
Clin Transplant 20:617-23. 2006..Patients with non-skin cancer after OLT had diminished long-term survival compared with the controls. Our results differ from other reports in the high incidence of gastrointestinal malignancies with attendant poor prognosis...